Cargando…

Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study

In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 (ChAd) vector vaccine followed by boosting with BN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Firinu, Davide, Perra, Andrea, Campagna, Marcello, Littera, Roberto, Meloni, Federico, Sedda, Francesca, Conti, Maria, Costanzo, Giulia, Erbi, Monica, Usai, Gianmario, Locci, Carlotta, Carta, Mauro Giovanni, Cappai, Riccardo, Orrù, Germano, Del Giacco, Stefano, Coghe, Ferdinando, Chessa, Luchino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704060/ https://www.ncbi.nlm.nih.gov/pubmed/34960224 http://dx.doi.org/10.3390/vaccines9121478

Ejemplares similares

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination
por: Firinu, Davide, et al.
Publicado: (2021)

Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy()
por: Firinu, Davide, et al.
Publicado: (2022)

Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination
por: Sanna, Giuseppina, et al.
Publicado: (2022)

COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome
por: Portoghese, Igor, et al.
Publicado: (2023)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
por: Lee, Tae Hwan, et al.
Publicado: (2023)

Covid-19 vaccines work but other factors play a relevant role: A data analysis on spread and mortality in 24 countries
por: Carta, Mauro Giovanni, et al.
Publicado: (2022)

BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
por: Abdul-Jawad, Sultan, et al.
Publicado: (2022)

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
por: Wei, Jie, et al.
Publicado: (2023)

Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults
por: Carta, Mauro Giovanni, et al.
Publicado: (2022)

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant
por: Sheikh, Aziz, et al.
Publicado: (2021)

Differences in lethality and diffusion of Covid-19 in countries using different kinds of vaccines
por: Carta, Mauro Giovanni, et al.
Publicado: (2022)

Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines
por: Kim, Ji Yeun, et al.
Publicado: (2021)

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
por: Richardson, Christopher D
Publicado: (2021)

Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination
por: Lim, So Yun, et al.
Publicado: (2021)

Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies
por: Radhwi, Osman O., et al.
Publicado: (2022)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature
por: Carta, Mauro Giovanni, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data
por: Cari, Luigi, et al.
Publicado: (2021)

Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
por: Shehab, Mohammad, et al.
Publicado: (2021)

COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
por: Heo, Jung Yeon, et al.
Publicado: (2022)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination
por: Catry, Emilie, et al.
Publicado: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
por: Agrati, Chiara, et al.
Publicado: (2021)

COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic
por: Costanzo, Giulia, et al.
Publicado: (2021)

Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination
por: Bauswein, Markus, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2021)

Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2
por: Lindhoff-Last, Edelgard, et al.
Publicado: (2021)

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea
por: Bae, Seongman, et al.
Publicado: (2021)

Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients
por: Lim, So Yun, et al.
Publicado: (2022)

Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency
por: Goda, Vera, et al.
Publicado: (2022)

Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
por: Chua, Jia Xin, et al.
Publicado: (2022)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_er35kbm1q9e26jl6ptbqson34u